CA3210294A1 - Compound and radioactive labeling compound - Google Patents

Compound and radioactive labeling compound Download PDF

Info

Publication number
CA3210294A1
CA3210294A1 CA3210294A CA3210294A CA3210294A1 CA 3210294 A1 CA3210294 A1 CA 3210294A1 CA 3210294 A CA3210294 A CA 3210294A CA 3210294 A CA3210294 A CA 3210294A CA 3210294 A1 CA3210294 A1 CA 3210294A1
Authority
CA
Canada
Prior art keywords
compound
psma
formula
atomic group
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3210294A
Other languages
English (en)
French (fr)
Inventor
Yoshifumi Maya
Hiroaki Ichikawa
Yusuke Higaki
Masahiro Ono
Shimpei IIKUNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Kyoto University
Original Assignee
Nihon Medi Physics Co Ltd
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Medi Physics Co Ltd, Kyoto University filed Critical Nihon Medi Physics Co Ltd
Publication of CA3210294A1 publication Critical patent/CA3210294A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3210294A 2021-03-04 2022-03-02 Compound and radioactive labeling compound Pending CA3210294A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021-034026 2021-03-04
JP2021034026 2021-03-04
JP2021-146833 2021-09-09
JP2021146833 2021-09-09
PCT/JP2022/009003 WO2022186311A1 (ja) 2021-03-04 2022-03-02 化合物及び放射性標識化合物

Publications (1)

Publication Number Publication Date
CA3210294A1 true CA3210294A1 (en) 2022-09-09

Family

ID=83155351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3210294A Pending CA3210294A1 (en) 2021-03-04 2022-03-02 Compound and radioactive labeling compound

Country Status (8)

Country Link
US (1) US20240174622A1 (cg-RX-API-DMAC7.html)
EP (1) EP4303213A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022186311A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230154183A (cg-RX-API-DMAC7.html)
AU (1) AU2022228911A1 (cg-RX-API-DMAC7.html)
CA (1) CA3210294A1 (cg-RX-API-DMAC7.html)
TW (1) TW202302542A (cg-RX-API-DMAC7.html)
WO (1) WO2022186311A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4196175A4 (en) * 2020-08-14 2025-07-30 Clarity Pharmaceuticals Ltd RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
CN116285684B (zh) * 2023-05-15 2023-08-08 四川绚度眼视光科技有限公司 一种多功能超亲水涂层及其制备方法与应用
CN116870176B (zh) * 2023-08-03 2025-08-12 浙江大学 PSMA靶向的PSMA-PARPi偶联物及制备方法和应用
WO2025220711A1 (ja) * 2024-04-17 2025-10-23 日本メジフィジックス株式会社 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
WO2026014283A1 (ja) * 2024-07-09 2026-01-15 日本メジフィジックス株式会社 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2760839C (en) 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
CN108699108B (zh) 2016-03-01 2022-04-08 国立大学法人千叶大学 放射性标记药物
CN109982998A (zh) * 2016-11-23 2019-07-05 癌靶技术有限责任公司 白蛋白结合psma抑制剂
KR102724812B1 (ko) * 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
CA3086454A1 (en) 2017-09-26 2019-04-04 National University Corporation Chiba University Radioactive drug
AU2018352731B2 (en) 2017-10-22 2023-10-05 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
KR102156385B1 (ko) * 2018-03-30 2020-09-15 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
KR20210116437A (ko) * 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
CA3118223A1 (en) * 2018-12-18 2020-06-25 Provincial Health Services Authority Dual mode 18f-labelled theranostic compounds and uses thereof
MX2021008230A (es) 2019-01-07 2021-08-11 Astellas Pharma Inc Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5.
MX2021013055A (es) * 2019-04-26 2021-12-10 Five Eleven Pharma Inc Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
TWI908773B (zh) * 2020-03-04 2025-12-21 日商日本醫事物理股份有限公司 化合物及放射性標誌化合物

Also Published As

Publication number Publication date
TW202302542A (zh) 2023-01-16
AU2022228911A1 (en) 2023-09-21
WO2022186311A1 (ja) 2022-09-09
KR20230154183A (ko) 2023-11-07
JPWO2022186311A1 (cg-RX-API-DMAC7.html) 2022-09-09
EP4303213A1 (en) 2024-01-10
US20240174622A1 (en) 2024-05-30
EP4303213A4 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
AU2023203682B2 (en) Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
JP7729609B2 (ja) 診断および放射性核種治療剤としての前立腺特異的膜抗原(psma)阻害剤
TWI908773B (zh) 化合物及放射性標誌化合物
JP7340459B2 (ja) 新規psma結合剤及びその使用
EP4303213A1 (en) Compound and radioactive labeling compound
CN108699108B (zh) 放射性标记药物
CA3071315A1 (en) Dual mode radiotracer and -therapeutics
WO2011031073A2 (ko) 신규한 테트라아자 거대고리 화합물, 제조방법 및 그 용도
CA3207132A1 (en) Dual mode radiotracer and -therapeutics
AU2023344993A1 (en) Platform and scaffold for FAP targeting agents
WO2024051794A1 (zh) 放射性核素偶联药物及其药物组合物和应用
EP2970154B1 (en) Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
JP2015086213A (ja) 放射性核種標識オクトレオチド誘導体
CA3214915A1 (en) Radiopharmaceutical somatostatin receptor ligands and precursors thereof
WO2013060793A1 (en) Bifunctional ligands for radiometals
WO2022233768A1 (en) Precursor and radiotracer for neuroendocrine theranostics
Riss et al. A concise synthesis procedure to furnish multi-gram amounts of hexadentate, bivalent DO2A-based chelators
WO2011102626A2 (ko) 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
RU2823164C2 (ru) Соединение пептидной природы, обладающее способностью связываться с псма, способ его получения и применения
HK40078050A (en) Compound and radioactive labeling compound
HK40092961A (en) Compound and radioactive labeling compound
CN116940557A (zh) 化合物及放射性标记化合物
Lodhi Synthesis and In Vivo Biological Evaluation of 99mTc (I) Tri-carbonyl Based Radiopharmaceuticals for SPECT Imaging
WO2025220711A1 (ja) 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
KR20250049308A (ko) 방사성 의약품용 규소계 불화물 수용기

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250214

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250214

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250214

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260202